AIDS and Behavior

, Volume 23, Issue 2, pp 548–555 | Cite as

Changes in Sexual Behavior and STI Diagnoses Among MSM Initiating PrEP in a Clinic Setting

  • Michalina A. MontañoEmail author
  • Julia C. Dombrowski
  • Sayan Dasgupta
  • Matthew R. Golden
  • Ann Duerr
  • Lisa E. Manhart
  • Lindley A. Barbee
  • Christine M. Khosropour
Original Paper


We examined changes in sexual behavior and sexually transmitted infection (STI) prevalence among 183 men who have sex with men (MSM) initiating pre-exposure prophylaxis (PrEP) at an STD Clinic in Seattle, WA. We used generalized estimating equations to measure changes in sexual behavior during PrEP use, and linked PrEP patient data with STI surveillance data to compare the prevalence of chlamydia, gonorrhea, and early syphilis in the periods prior to and during PrEP use. Reporting never using condoms in the prior 30 days increased (adjusted relative risk = 1.46; 95% confidence interval 1.13, 1.88) at 12 months after PrEP initiation compared to the initial PrEP visit. Reporting unknown status partners in the prior 30 days decreased at 12 months compared to the initial PrEP visit, but there was no change in number of sexual partners or reporting HIV-positive or HIV-negative partners. The percentage of patients diagnosed with any STI while using PrEP (49.2%) was higher than the percentage diagnosed in the 12 months prior to PrEP use (35.0%), likely driven in part by increased STI screening during PrEP use. Among MSM on PrEP, we observed decreases in condom use, and a higher prevalence of STIs during PrEP use compared to prior to PrEP initiation.


Men who have sex with men HIV Pre-exposure prophylaxis Sexually transmitted infections Sexual behavior 



We wish to thank the staff at the PHSKC STD Clinic, including C. Malinski, G. Afful, M. Barry, S. Herrmann, N. Ocbamichael, C. Thibault, D. Spellman, and J. Dimer. This work was funded by Public Health – Seattle and King County; the National Institutes of Health (NIH) [F31 MH114892 trainee support to MAM, and K23 AI113185 to LAB]; and the University of Washington Center for AIDS Research, an NIH-funded Program [P30 AI027757] which is supported by the following NIH Institutes and Centers: National Institute of Allergy and Infectious Diseases, National Cancer Institute, National Institutes of Mental Health, National Institute on Drug Abuse, National Institute of Child Health and Human Development, National Heart, Lung, and Blood Institute, and National Institute on Aging.

Compliance with Ethical Standards

Conflict of interest

CMK, MRG, LAB and LEM have received donations of specimen collection kits and reagents from Hologic, Inc. unrelated to this work. LEM has received speaker’s fees from Hologic, Inc. unrelated to this work. JCD has conducted studies unrelated to this work funded by grants to the University of Washington from Hologic, Curatek, and Quidel, and has received a speaker’s honorarium and travel support for a meeting on retention in HIV care from Gilead. MRG has received research support from GlaxoSmithKline. MAM, SD, and AD declare that they have no conflict of interest.

Ethical Approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed Consent

For this type of study formal consent is not required.


  1. 1.
    Centers for Disease Control and Prevention. HIV surveillance report: diagnoses of HIV infection in the United States and dependent areas, 2016. Atlanta; 2016.Google Scholar
  2. 2.
    McCormack S, Dunn DT, Desai M, Dolling DI, Gafos M, Gilson R, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet. 2015;387(10013):53–60.CrossRefPubMedGoogle Scholar
  3. 3.
    Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587–99.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Grant RM, Anderson PL, McMahan V, Liu A, Amico KR, Mehrotra M, et al. Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet Infect Dis. 2014;14(9):820–9.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Marcus JL, Volk JE, Pinder J, Liu AY, Bacon O, Hare CB, et al. Successful implementation of HIV preexposure prophylaxis: lessons learned from three clinical settings. Curr HIV/AIDS Rep. 2016;13(2):116–24.CrossRefPubMedGoogle Scholar
  6. 6.
    Eaton L, Kalichman S. Risk compensation in HIV prevention: implications for vaccines, microbicides, and other biomedical HIV prevention technologies. Curr Opin HIV AIDS. 2007;4(4):165–72.CrossRefGoogle Scholar
  7. 7.
    Hogben M, Aral SO. Risk compensation in the age of biomedical prevention. Focus (San Fr CA). 2010;24(4):5–7.Google Scholar
  8. 8.
    Cassell MM, Halperin DT, Shelton JD, Stanton D. Risk compensation: the Achilles’ heel of innovations in HIV prevention? Br Med J. 2006;332(7541):605–7.CrossRefGoogle Scholar
  9. 9.
    Marcus JL, Glidden DV, Mayer KH, Liu AY, Buchbinder SP, Amico KR, et al. No evidence of sexual risk compensation in the iPrEx trial of daily oral HIV preexposure prophylaxis. PLoS ONE. 2013;8(12):e81997.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Volk JE, Marcus JL, Phengrasamy T, Blechinger D, Nguyen DP, Follansbee S, et al. No new HIV infections with increasing use of HIV preexposure prophylaxis in a clinical practice setting. Clin Infect Dis. 2015;61(10):1601–3.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Oldenburg CE, Nunn AS, Montgomery M, Almonte A, Mena L, Patel RR, et al. Behavioral changes following uptake of HIV pre-exposure prophylaxis among men who have sex with men in a clinical setting. AIDS Behav. 2018;22:1075–9.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Marcus JL, Hurley LB, Hare CB, Nguyen DP, Phengrasamy T, Silverberg MJ, et al. Preexposure prophylaxis for HIV prevention in a large integrated health care system: adherence, renal safety, and discontinuation. J Acquir Immune Defic Syndr. 2016;73(5):540–6.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Centers for Disease Control and Prevention. Sexually transmitted disease surveillance 2016. Atlanta GA; 2017.Google Scholar
  14. 14.
    Public Health – Seattle & King County. Pre-exposure prophylaxis (PrEP) implementation guidelines 2015 [Internet]. 2015 [cited 2017 Oct 11].
  15. 15.
    Liu A, Vittinghoff E, Chillag K, Mayer K, Thompson M, Grohskopf L, et al. Sexual risk behavior among HIV-uninfected men who have sex with men (MSM) participating in a tenofovir pre-exposure prophylaxis (PrEP) randomized trial in the United States. J Acquir Immune Defic Syndr. 2013;64(1):87–94.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Guest G, Shattuck D, Johnson L, Akumatey B, Clarke EEK, Chen P-L, et al. Changes in sexual risk behavior among participants in a PrEP HIV prevention trial. Sex Transm Dis. 2008;35(12):1002–8.PubMedGoogle Scholar
  17. 17.
    Stenger MR, Pathela P, Anschuetz G, Bauer H, Simon J, Kohn R, et al. Increases in the rate of Neisseria gonorrhoeae among gay, bisexual and other men who have sex with men—findings from the sexually transmitted disease surveillance network 2010–2015. Sex Transm Dis. 2017;44(7):393–7.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Patton ME, Su JR, Nelson R, Weinstock H. MMWR: primary and secondary syphilis—United States, 2005–2013. Morb Mortal Wkly Rep. 2014;63(18):402–6.Google Scholar
  19. 19.
    Public Health Seattle & King County. King County sexually transmitted diseases epidemiology report. 2015;1–67.Google Scholar
  20. 20.
    Jenness SM, Weiss KM, Goodreau SM, Gift T, Chesson H, Hoover KW, et al. Incidence of gonorrhea and chlamydia following human immunodeficiency virus preexposure prophylaxis among men who have sex with men: a modeling study. Clin Infect Dis. 2017;65(5):712–8.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Michalina A. Montaño
    • 1
    Email author
  • Julia C. Dombrowski
    • 2
    • 5
  • Sayan Dasgupta
    • 3
  • Matthew R. Golden
    • 1
    • 2
    • 5
  • Ann Duerr
    • 1
    • 3
    • 4
  • Lisa E. Manhart
    • 1
    • 4
  • Lindley A. Barbee
    • 2
    • 5
  • Christine M. Khosropour
    • 1
  1. 1.Department of EpidemiologyUniversity of WashingtonSeattleUSA
  2. 2.Department of MedicineUniversity of WashingtonSeattleUSA
  3. 3.Fred Hutchinson Cancer Research CenterSeattleUSA
  4. 4.Department of Global HealthUniversity of WashingtonSeattleUSA
  5. 5.Public Health – Seattle and King County HIV/STD ProgramSeattleUSA

Personalised recommendations